scholarly article | Q13442814 |
P50 | author | Leyi Wang | Q42411029 |
Dianjun Cao | Q58428833 | ||
Xiang-Jin Meng | Q88025910 | ||
Ming Tan | Q115232766 | ||
P2093 | author name string | Ming Xia | |
Pengwei Huang | |||
Xi Jiang | |||
Hao Fang | |||
Monica McNeal | |||
P2860 | cites work | Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial | Q45189946 |
Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development | Q45358131 | ||
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry | Q46851930 | ||
Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. | Q54294858 | ||
E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability. | Q54497752 | ||
Porcine circovirus type 2 (PCV2) viral components immunomodulate recall antigen responses | Q57207435 | ||
Amgen swallows Micromet to BiTE into ALL market | Q83852281 | ||
The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors | Q24563224 | ||
Structural basis for the recognition of blood group trisaccharides by norovirus | Q24682901 | ||
X-ray structure of glutathione S -transferase from the malarial parasite Plasmodium falciparum | Q27642569 | ||
Structural Basis for the Receptor Binding Specificity of Norwalk Virus | Q27650214 | ||
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus | Q27651029 | ||
Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction | Q27656916 | ||
Crystal structure of the human astrovirus capsid spike | Q27670881 | ||
Crystallography of a Lewis-Binding Norovirus, Elucidation of Strain-Specificity to the Polymorphic Human Histo-Blood Group Antigens | Q27671411 | ||
Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. | Q32180102 | ||
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns | Q33788719 | ||
Subviral particle as vaccine and vaccine platform | Q33812653 | ||
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection | Q34054427 | ||
The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors | Q34123964 | ||
Serological Correlate of Protection against Norovirus‐Induced Gastroenteritis | Q34153875 | ||
Molecular virology of hepatitis E virus | Q34166393 | ||
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production | Q34485266 | ||
Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles | Q34724844 | ||
C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein. | Q35023707 | ||
A candidate dual vaccine against influenza and noroviruses | Q35301295 | ||
Serological evidence for a hepatitis e virus-related agent in goats in the United States | Q36420009 | ||
Noroviral P particle: structure, function and applications in virus-host interaction | Q36429481 | ||
Polyvalent complexes for vaccine development | Q36792270 | ||
Norovirus vaccine against experimental human Norwalk Virus illness | Q37144052 | ||
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
A dual vaccine candidate against norovirus and hepatitis E virus | Q37502688 | ||
Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design | Q37792984 | ||
Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns | Q38353300 | ||
Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine | Q39681193 | ||
Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay | Q40316613 | ||
P433 | issue | 29 | |
P304 | page(s) | 8427-8438 | |
P577 | publication date | 2014-06-28 | |
P1433 | published in | Biomaterials | Q15751139 |
P1476 | title | Branched-linear and agglomerate protein polymers as vaccine platforms | |
P478 | volume | 35 |
Q36519453 | A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus |
Q35152899 | Affinities of human histo-blood group antigens for norovirus capsid protein complexes |
Q91576751 | Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform |
Q47547891 | Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model. |
Q36914794 | Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus |
Q104289416 | Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine |
Q34160482 | Gangliosides are ligands for human noroviruses |
Q30234848 | Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy |
Q92759295 | Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice |
Q90231715 | Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development |
Q36275589 | Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives |
Q38819439 | Recent advancements in combination subunit vaccine development |
Q57154565 | Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection |
Search more.